MARKET OUTLOOK

Rheumatoid arthritis (RA) is a chronic and progressive autoimmune disease that primarily affects the joints. China has globally the highest number of RA patients, and the Chinese RA market boasts six biologics: the TNF-α inhibitors etanercept (Amgen’s Enbrel, biosimilars), adalimumab (AbbVie’s Humira), infliximab (Janssen’s Remicade), and golimumab (Janssen’s Simponi); theIL-6 inhibitor tocilizumab (Roche’s Actemra); the B-cell modulator rituximab (Roche’s MabThera, biosimilars); and the oral JAK inhibitor Xeljanz (tofacitinib). The TNF-α inhibitors are the most widely prescribed targeted therapies for RA patients refractory to conventional DMARDs, and other biologics and the JAK inhibitor tofacitinib largely compete for use in TNF-α-inhibitor-refractory patients. With the expected launch of additional targeted therapies, in addition to the availability of the cost-effective biosimilars of marketed TNF-α inhibitors during the forecast period, the Chinese RA market will witness fierce competition and increasing challenges to gain market uptake.

  • How large is China’s drug-treatable RA population and how will the drug-treatment rate change during the forecast period?
  • Which are the most commercially relevant drugs in China’s RA market and why? What are interviewed experts’ insights on current treatment options? Which clinical needs remain unfulfilled?
  • What are the key market access considerations of key therapies in the RA pipeline in China? What sales/uptake could they secure in RA? What are interviewed experts’ opinion on the key emerging therapies?
  • What are the key drivers and constraints in the China RA market, and how will the market evolve over the forecast period?

PRODUCT DESCRIPTION

China In-Depth: Comprehensive market intelligence providing world-class epidemiology, keen insight into the China specific access & reimbursement environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Release date

June 2019

Geographies

China

Primary Research

Qualitative and quantitative insights driven by 5 country-specific interviews with thought-leading rheumatologists, supported by survey data collected for this and other DRG research.

Epidemiology

Diagnosed prevalence of RA by disease stage. Clinically and market relevant drug-treatable populations.

FORECAST

10-year, annualized, drug-level sales and patient shares of key RA therapies through 2028, based on primary and secondary market research to formulate bottom-up assumptions

EMERGING THERAPIES

Phase III/PR: 8 drugs; Phase II: 2 drugs; Coverage of select early-phase products.


Related Reports

Rheumatoid Arthritis - Landscape & Forecast - Disease Landscape & Forecast

The increasingly crowded RA market boasts many targeted agents representing several different drug classes, including blockbuster

View Details

Rheumatoid Arthritis | Disease Landscape and Forecast | G7 | 2020

The increasingly crowded RA market boasts many targeted agents representing several different drug classes, including blockbuster TNF-α inhibitors, five non-TNF-α biologics (including the second IL...

View Details

Rheumatoid Arthritis - Current Treatment - Rheumatoid Arthritis | Treatment Algorithms: Claims Data Analysis | US | Dashboard

MARKET OUTLOOK Rheumatoid arthritis (RA) is characterized by chronic and progressive joint inflammation that commonly leads to permanent, debilitating tissue damage and cartilage and bone d...

View Details

Rheumatoid Arthritis - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)

MARKET OUTLOOKRheumatoid arthritis (RA) is characterized by chronic and progressive joint inflammation that commonly leads to permanent, debilitating tissue damage and cartilage and bone des...

View Details